There's been an alarming increase of respiratory and gastrointestinal viruses in the United States lately, causing anxiety about a so-called "quad-demic". According to surveillance reports, influenza, COVID-19, RSV and norovirus are at very high levels everywhere. While the surge aligns with patterns typical for this season, several epidemiologists view simultaneous infections of such proportions to pose risks not only to individual healthcare but public health.

The incidence of the quad-demic should vary with seasonal patterns, vaccination rates, and public health interventions. Each virus alone is relatively easy to manage; however, the effect of all together could lead to overburdening of health care facilities and increase risks for those at higher risk. Continuing surveillance, early testing, and proactive prevention measures will play an important role in the control of these infections going forward.

While the term "quad-demic" sounds daunting, it must be taken into perspective. For years, we have had all these viruses together, and we have the capabilities to mitigate some of the risk. Vaccination, proper hygiene and using common sense helps individuals get through the season unscathed. Is the quad-demic a permanent fixture or just another seasonal wave? Let's break this down.

What is the Quad-demic?

Typically, flu, COVID-19, and RSV have been the primary culprits behind seasonal respiratory infections. However, norovirus, a highly contagious stomach bug, has emerged as a fourth significant player, inducing fears of a more severe and widespread viral outbreak. According to the Centers for Disease Control and Prevention (CDC), the U.S. recorded nearly 500 norovirus outbreaks between August and December 2023, a substantial rise from the previous year’s numbers.

While the term "quad-demic" may sound ominous, the seriousness and consequences of such infections should be weighed in light of the U.S. healthcare system's experience with managing viral surges since the start of the COVID-19 pandemic.

1. Influenza (Flu)

Flu continues to be one of the most common and alarming seasonal illnesses. In the period spanning from 2023 to 2024, there were approximately 40 million cases of flu, and thousands of hospitalizations along with reported 47 deaths have been reported this season. Flu symptoms include fever, chills, cough, sore throat, muscle pain, and fatigue, with most recovering within a week or two but risky factors for severe illness effects occur in young children, elderly, and people with chronic conditions.

2. Covid-19

Despite its reduction from the first pandemic peak, COVID-19 is still rampant. The CDC estimates that alone between October and December 2023, there were between 2.7 and 5 million cases in the U.S. Hospitalization has increased by cities such as Los Angeles, Chicago, and New York. Symptoms are closely similar to the flu, fever, cough, and fatigue but uniquely presents in some cases as loss of taste and smell.

3. RSV

RSV is the most common cause of lower respiratory infections in infants, older adults, and immunocompromised individuals. While RSV peaked late in 2023 and early 2024, it continues to be a threat because it can lead to bronchiolitis and pneumonia. It is very similar to the common cold, presenting with symptoms such as congestion, runny nose, coughing, and fever, which can make it difficult to differentiate from flu or COVID-19 without testing.

4. Norovirus

Norovirus, also called the "stomach flu," is a highly contagious infection of the gastrointestinal tract, not a respiratory virus. It transmits quickly from contaminated food and water and contact with contaminated surfaces, causing such symptoms as diarrhea, vomiting, nausea, and stomach pain. Cases have shot up, the CDC said Monday, with reports of outbreaks surging compared with last year.

Is There a Challenge In Diagnosis Due to Overlapping Symptoms?

The greatest challenge during the quad-demic is how the four viruses are alike and thus make identification very hard with no testing applied. Most cases present symptoms common to all viruses: fever, tiredness, body pains, and respiratory, which includes coughing and congestions for influenza, COVID-19, and RSV; the other would be norovirus symptoms as nausea and vomiting can appear even in extreme influenza and COVID-19. This overlap increases the risk of misdiagnosis and delayed treatment, hence the need for early testing and proper medical guidance.

Also Read: Is US Preparing For A Quad- demic 2025?

Effective Prevention Strategies That Work

The best defense against these viruses is a combination of vaccines, hygiene, and lifestyle precautions. While lifestyle modifications are highlighted as part of the constant need to eat healthy, ensure daily movement and drinking adequate amount of fluids. There is a sure short two preventive strategies that are effective:

Vaccination

• Flu vaccine: Annual flu shots reduce the severity of infection, allergic flare ups and hospitalizations.
• COVID-19 vaccine: Though COVID-19 cases have declined, vaccination remains critical in preventing severe outcomes.
• RSV vaccine: Available for those aged 60 years and older, especially those with underlying conditions.
• Norovirus vaccine: No vaccine is yet available, but mRNA vaccine research is in progress.

Hygiene and Sanitation

• Washing hands frequently with soap and water for at least 20 seconds, especially after public exposure.
• Disinfect frequently touched surfaces regularly, use sanitiser when outside.
• Avoid close contact with infected people and wear masks.

Do You Need To Wear A Mask All The Time?

While debates on masked wear continue on, experts on mask-wear affirm that this does not only have a historical precedent but works towards reducing airborne viruses spreading within the environments. Hospitals, though, ensure masking in key sections of themselves. Publicized mask-wear remains a discretion, though massing indoors still goes a longer way in cases like peak flu seasons.

If you notice the symptoms of these viruses, then it's best to be confined at home and avoid having face-to-face interaction with others and seek immediate attention from your physician if your condition worsens. Quarantining for some days can decrease the spread of infection.

As we move into the first half of 2025 and beyond, staying informed and proactive is the best strategy for maintaining health and avoiding unnecessary panic. The key takeaway? Stay vigilant, but don’t be alarmed—these viruses are here, but so are the means to fight them.

India continues to battle one of the world's highest burdens of preterm births. Early identification of critically ill newborns remains crucial for improving survival rates, particularly in hospitals with limited resources.

A new Indian study says that Clinical Risk Index for Babies-II (CRIB-II) score is an effective tool for predicting mortality risk among preterm newborns admitted to neonatal intensive care units (NICUs).

The research, conducted by doctors at JK Lone Hospital in Jaipur and published in the International Journal of Paediatric Research, can help preterm babies receive faster treatment and enable better use of neonatal intensive care resources.

What Is The CRIB-II score?

• Birth weight
• Gestational age
• Baby's body temperature at admission
• Blood acid-base status
• Sex of the baby

The higher the score, the greater the risk of severe illness or death.

What Did The Study Find?

Researchers studied 181 premature newborns admitted to the tertiary care hospital. The babies had an average gestational age of 28.88 weeks and an average birth weight of 1.01 kg. The analysis showed a clear relationship between CRIB-II scores and outcomes:

• 0 to 5: Low risk
• 6 to 10: Moderate risk
• 11 to 15: High risk
• Above 15: Very high risk

Babies with higher CRIB-II scores were significantly more likely to die than those with lower scores, suggesting that the scoring system can accurately identify newborns requiring immediate intensive care.

Early Risk Assessment Can Save Lives

Also read: Beyond The Bump: Why Preconceptions And Antenatal Care Are Key To A Healthy Pregnancy

Dr. Yogesh Yadav, paediatric specialist and one of the study's researchers, said the score enables doctors to make critical treatment decisions within the first few hours after admission.

"If we calculate the CRIB-II score at the time of admission, we can understand the seriousness of the baby's condition. This helps doctors decide the right treatment direction early and increases the chances of saving the baby."

He added that the score is more than simply a predictor of mortality. "CRIB-II is not just a score to predict death risk, but an important scientific tool for decision-making in the NICU. In the first few hours, we can identify which newborn is at high risk."

The researchers believe the scoring system could be particularly valuable across India, where NICUs often face shortages of beds, ventilators and trained neonatal staff.

According to Dr. Yadav: "When beds, ventilators or trained staff are limited, babies with higher scores can be given priority in the NICU. It also helps in deciding which newborns need to be referred immediately to higher centres."

The score can also improve communication with families by helping clinicians provide clearer information about a baby's condition and expected prognosis.

"Through CRIB-II, we can give parents a clearer and more accurate understanding of the baby's condition, possible outcomes and treatment needs."

Although CRIB-II has been used internationally for years, the latest Indian findings add to growing evidence supporting its use in neonatal intensive care.

A newly identified brain protein may help slow the progression of Alzheimer's disease, according to new research that sheds light on how the disease spreads through the brain.

Scientists have found that a protein called SORLA acts as a natural defense against the toxic tau protein, limiting the brain damage that causes memory loss and cognitive decline.

The findings, published in Nature Neuroscience, suggest that boosting SORLA activity could become a therapeutic strategy.

SORLA Can Help Regulate Tau

The study found that SORLA regulates how tau proteins move between neurons. While amyloid plaques have long dominated Alzheimer's research, mounting evidence suggests that the spread of tau in the brain is more closely linked to the symptoms of Alzheimer's.

When SORLA levels were low, toxic tau spread more easily from one brain cell to another. In contrast, increasing SORLA significantly reduced tau accumulation, protected brain tissue from shrinking, and preserved memory in mouse models of Alzheimer's disease.

"Our findings identify SORLA as a potent endogenous suppressor of tau propagation," the researchers wrote, adding that enhancing SORLA function "could represent a promising therapeutic strategy for limiting the progression of Alzheimer's disease."

Also read: Alzheimer's Drug Leqembi Helps Over 75% Of Patients Remain Stable Or Improve: Real-World Study

How Can This Discovery Help?

Current Alzheimer's drugs like Leqembi primarily target amyloid-beta plaques. Although these treatments can slow disease progression in some patients, they do not directly stop the spread of tau, which drives the loss of brain cells which worsens dementia.

The discovery of SORLA offers a different approach by targeting one of the disease's most dangerous aspects: tau propagation.

Can This Lead To Effective Alzheimer's Treatments?

The SORLA findings were demonstrated primarily in laboratory models, meaning much more research is needed before therapies can be tested in people.

However, researchers say identifying the brain's own protective mechanisms provides an important roadmap for developing treatments that not only remove harmful proteins but also prevent them from spreading.

If future studies confirm these findings in humans, therapies that boost SORLA could potentially be combined with existing anti-amyloid medicines to slow Alzheimer's progression more effectively.

The SORLA discovery comes amid growing momentum in tau-based Alzheimer's research.

Just this month, researchers reported encouraging results from diranersen, an experimental therapy designed to reduce production of the tau protein itself.

In a mid-stage clinical trial involving around 400 people with early Alzheimer's disease, the drug lowered tau levels and showed signs of slowing cognitive decline in some participants, although larger studies are needed to confirm its effectiveness.

Also read: Excessive TV Watching In Midlife May Shrink Brain Areas Essential For Memory, Study Finds

What Is SORLA?

SORLA (Sorting Protein-Related Receptor with LDLR Class A Repeats) is a receptor protein naturally present in brain cells.

Scientists have known for years that low SORLA levels are associated with an increased risk of Alzheimer's disease because the protein helps process amyloid precursor protein.

Why Is Tau Considered Dangerous?

Tau is a normal protein that helps stabilize the internal structure of nerve cells. In Alzheimer's disease, however, tau becomes abnormally folded and forms neurofibrillary tangles.

These tangles spread through interconnected brain regions, disrupting communication between neurons, and eventually causing them to die.

Researchers believe the progression of tau pathology closely mirrors the progression of memory loss and cognitive impairment seen in Alzheimer's patients.

Women with polyendocrine metabolic ovarian syndrome (PMOS)—formerly known as polycystic ovarian syndrome (PCOS)—face a significantly higher risk of heart attacks, strokes, and other cardiovascular diseases, according to a large study published in The Lancet Obstetrics, Gynaecology & Women's Health.

PMOS affects an estimated 10–13% of women of reproductive age. Researchers analyzed data from more than 2 million women and found that those with PMOS had a substantially higher risk of serious cardiovascular events, even after accounting for established risk factors such as obesity, diabetes, high blood pressure, smoking, and high cholesterol.

The findings, by researchers from the University of Pennsylvania and the University of Rochester, suggest that PMOS should be recognized not only as a reproductive health condition but also as a major cardiometabolic disorder, underscoring the need for routine cardiovascular monitoring in affected women.

What Did The Study Find?

Also read: PCOS Is Now PMOS: What The Name Change Means For Millions Of Women

Women with PMOS were significantly more likely to develop atherosclerotic cardiovascular disease (ASCVD), including heart attacks and strokes.

After adjusting for traditional cardiovascular risk factors, researchers found that women with PMOS were:

• 2.5 times more likely to experience a heart attack or stroke.
• 3.4 times more likely to have a transient ischemic attack (TIA), or "mini-stroke."
• Nearly four times more likely to develop peripheral artery disease (PAD), in which narrowed arteries reduce blood flow to the limbs.

"Our work shows that it is imperative for clinicians to closely track and evaluate cardiovascular health in patients with PMOS," said Dr. Anuja Dokras, senior author of the study and Founders Professor of Women's Health at the University of Pennsylvania.

She advised women with PMOS to lower their cardiovascular risk by:

• Avoiding smoking
• Staying physically active
• Maintaining a healthy weight
• Regularly monitoring blood pressure, cholesterol, and blood sugar

What Is PMOS?

PMOS is the new name for PCOS, adopted following an international consensus announced in May 2026 by the World Health Organization, the Endocrine Society, and other leading organizations.

The new name reflects the understanding that the condition affects multiple body systems—not just the ovaries. PMOS is a complex hormonal and metabolic disorder linked to an increased risk of:

• Infertility
• Type 2 diabetes
• Endometrial cancer
• Cardiovascular disease

The condition can affect:

• Endocrine health
• Metabolic health
• Reproductive health
• Dermatological health
• Psychological health

Why Was PCOS Renamed?

Experts said the term PCOS was misleading because many patients believed it referred to ovarian cysts, whereas the condition is characterized by increased ovarian follicles rather than true cysts.

"My patients often assumed they had cysts on their ovaries, but instead, people with PMOS have increased follicles that can resemble cysts," said Dr. Dokras. "The effects of PMOS extend far beyond gynecologic health. The new name better reflects the multiple hormonal and metabolic systems involved and encourages more comprehensive care."

The new name aims to explain the condition more accurately and comprehensively.

• Polyendocrine means it affects multiple hormones in the body.
• Metabolic refers to issues linked to weight, insulin, blood sugar, and heart health.
• Ovarian highlights its impact on ovulation and reproductive health.
• Syndrome refers to a group of symptoms occurring together.